Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase NA 5Phase 2 1Phase 1/2 1

Status

Unknown 4Completed 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 155Neoplasms 115Colorectal Neoplasms 97Breast Neoplasms 92Pancreatic Neoplasms 80Neoplasm Metastasis 80Leukemia, Myeloid, Acute 79Recurrence 76Melanoma 74Prostatic Neoplasms 73Ovarian Neoplasms 73Multiple Myeloma 66Stomach Neoplasms 59Squamous Cell Carcinoma of Head and Neck 55Lung Neoplasms 55Triple Negative Breast Neoplasms 50Glioblastoma 48Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 42Advanced Solid Tumor 42Lymphoma, Non-Hodgkin 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Advanced Solid Tumors 37Small Cell Lung Carcinoma 35Uterine Cervical Neoplasms 34Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Drug-Related Side Effects and Adverse Reactions × Clear all
NCT06789601 2025-06-19

Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository

Brigham and Women's Hospital

Phase 1/2 Recruiting
100 enrolled

Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡